Partners

BioGenCell has started developing a worldwide strategic partner network dedicated to developing and improving patient access to its groundbreaking technology and products.

  • Sanz Medical Center (Laniado Hospital, Netanya, Israel)
    The BioGenCell team has a very close working relationship with the hospital’s expert medical team members including Dr. Mark Niven (Director of the Endocrine and Diabetes Unit), Dr. Galit Sivak (Director of Vascular Surgery) and Dr. Shlomo Bulvic (Head of the Haematology Department).
    Sanz Medical Center–Laniado Hospital offers its services to over 250,000 people through its various departments and out-patient clinics, including internal medicine, ophthalmology, pediatrics, surgery, ENT, intensive care, gynecology, dialysis, hematology, gastroenterology, oncology, angiography, and orthopedics. The medical center uses the most modern methods: its instruments, equipment, and expert staff have given the Sanz Medical Center its reputation as one of the leading hospitals in Israel.
    Laniado Hospital’s motto: “The hospital will aid every person, and this aid will not be technical assistance alone—it will come from the heart. In this hospital, the staff will work as professionals without forgetting the most important aspects of compassion, warmth, and empathy for the patient.”If you are interested in joining our partner program, please send us an email at partners@BioGenCell.net
  • BioGenCell Collaborates with Newcastle University.
    BioGenCell has joined forces with Newcastle University Institute of Cellular Medicine, Institute for Cell and Molecular Bioscience and North East England Stem Cell Institute together with the Laniado diabetes center in Israel, for research on a new regenerative medicine. Both parties have embarked on a collaborative venture, bringing together different cell therapies that are currently pioneered in both countries towards a simple and persuasive new combination therapeutic of donor-derived pancreatic islets and patient’s own endothelial progenitor cells.
    Together, Prof. Shaw, Professor of Regenerative Medicine for Diabetes and Honorary Consultant Physician, Institute of Cellular Medicine, Institute for Cell and Molecular Bioscience and North East England Stem Cell Institute and Dr. Niven, Director of Endocrine and Diabetes Unit at Laniado Hospital, Israel, are generating a new concept for potentially transforming islet transplant clinical outcomes and are excited about the results of their first joint research grant. The purpose is to produce a novel donor human islet: recipient enriched endothelial progenitor cell combination therapy which will enable rapid reestablishment of a healthy blood supply for the insulin-producing cells after transplantation into the liver.
    Preliminary research results show that bringing together experts in islet transplant innovations from Newcastle University, and BioGenCell’s novel patient specific blood-derived therapeutic stem/progenitor cells has real potential for clinical implementation of an entirely new therapeutic combination, perhaps even in the very near future.